3-cyano-quinoline derivatives with antiproliferative activity

Details 3-cyano-quinoline derivatives with antiproliferative activity 3-cyano-quinoline derivatives with antiproliferative activity

2004-12-15

2010-02-02

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S471000

Reexamination Certificate

active

07655642

ABSTRACT:
The present invention concerns the compounds of formulathe N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, whereinZ represents NH;Y represents —C3-9alkyl-, —C1-5alkyl-NR12—C1-5alkyl-, —C1-6alkyl-NH—CO— or —CO—NH—C1-6alkyl-;X1represents —O—;X2represents a direct bond, —NR11—C1-2alkyl-, —NR11—CH2—, —C1-2alkyl-, —O—C1-2alkyl, —O— or —O—CH2—;R1represents hydrogen or halo;R2represents hydrogen, cyano, halo, hydroxycarbonyl-, C1-4alkyloxycarbonyl-, Het16-carbonyl- or Ar5;R3represents hydrogen, hydroxy, C1-4alkyloxy-, Ar4—C1-4alkyloxy or R3represents C1-4alkyloxy substituted with one or where possible two or more substituents selected from C1-4alkyloxy- or Het2-;R10represents hydrogen;R11represents hydrogen, C1-4alkyl- or C1-4alkyl-oxy-carbonyl-;R12represents Het14-C1-4alkyl, in particular morpholinyl-C1-4alkyl;Het2represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C1-4alkyl-, preferably methyl;Het14represents morpholinyl;Het16represents a heterocycle selected from morpholinyl or pyrrolidinyl;Ar4represents phenyl;Ar5represents phenyl optionally substituted with cyano.

REFERENCES:
patent: 6002008 (1999-12-01), Wissner et al.
patent: 6288082 (2001-09-01), Wissner et al.
patent: WO 98/43960 (1998-10-01), None
patent: WO 00/18761 (2000-04-01), None
patent: WO 03/082290 (2003-10-01), None
patent: WO 2004/105765 (2004-12-01), None
“Psoriasis”, http://www.nlm.nih.gov/cgi/mesh/2008/MB—cgi, accessed Nov. 21, 2008.
Whitley et al. Proceedings of the American Association of Cancer Research, 2004, 45, abstract 4918.
Rusnak et al. Cancer Research, 2001, 61(19), 7196-7203.
Brown et al., “High Throughput Screening”, 1997, editors: Devlin, John P., Publishers: Dekker, New York, N. Y., pp. 317-328.
Burke, Terrence R. Jr., “Protein-tyrosine Kinase Inhibitors”,Drugs of The Future, 1992, pp. 119-131, vol. 17, No. 2.
Davies et al., “Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors”,Biochemical Society, 2000, pp. 95-105, vol. 351.
Delia, Thomas, “Fused Pyrimidines, Part Four, Miscellaneous Fused Pyrimidines: Chapter VI-Pyrimidotriazines.”,Heterocyclic Compounds, John Wiley & Sons, Inc., Interscience Publications, pp. 261-304.
Druker et al., “Lessons Learned From The Development of An Abl Tyrosine Kinase Inhibitor For Chronic Myelogenous Leukemia”,The Journal of Clinical Investigation, Jan. 2000, pp. 3-7, vol. 5, No. 1.
Elder et al., “Overexpression of transforming growth factor alpha in psoriatic epidermis”,Science, 1989, pp. 811-814, vol. 243.
Gennaro et al.Remington's Pharmaceutical Sciences, 19thed., Mack Publishing Company, 1990, see especially Part 8 : Pharmaceutical preparations and their Manufacture.
Greene et al., “Protective Groups in Organic Synthesis”, 2ndedition, Wiley Interscience, 1991.
Hennequin, et al.: “Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors”,Journal of Medicinal Chemistry, Mar. 14, 2002, pp. 1300-1312, vol. 45, No. 6, American Chemical Society, Washington, US, XP002256124.
Morin, Michael J., “From Oncogene to Drug: Development of Small Molecule Tyrosine Kinase Inhibitors as Anti-tumor and Anti-angiogenic Agents”,Oncogene, 2000, pp. 6574-6583, vol. 19.
Nagamatsu et al., “Sytheses of 3-Substituted 1-Methyl-6-Phenylpyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones (6-Phenyl Analogs of Toxoflavin) and Their 4-Oxides, and Evaluation of Antimicrobial Activity of Toxoflavins and Their Analogs.”,Chem Pharm Bull., 1993, pp. 362-368. vol. 41, No. 2.
Nagamatsu et al., “General Syntheses of 1-Alkyltoxoflavin and 8-Alkylfervenulin Derivatives of Biological Significance By The Regioselective Alylation of Reumycin Derivatives And The Rates of Transalkylation From 1-Alkyltoxoflavins Into Nucleophiles.”,J. Chem. Soc. Perkin Trans. 1, 2001, pp. 130-137.
Palmer, B.D. et al.: “Tyrosine Kinase Inhibitors 11 Soluble Analogs of Pyrrolo-and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation, and Modeling of the Mode of Binding”,Journal of Medicinal Chemistry, 1997, pp. 1519-1529, vol. 40, No. 10, American Chemical Society, Washington, US, XP002094613.
Shawver et al., “Smart Drugs: Tyrosine Kinase Inhibitors In Cancer Therapy”,Cancer Cells, Mar. 2002, pp. 117-123, vol. 1.
Wissner et al., “4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile Inhibitors of Epidermal Growth Factor Receptor Kinase And Their Bioisosteric Relationship To The 4-Anilino-6,7-dialkoxyquinazoline Inhibitors”,Journal of Medicinal Chemistry, 2000, pp. 3244-3256, vol. 43, No. 17, American Chemical Society, Washington, US.
PCT Intl. Search Report, PCT/EP2004/053497,Apr. 12, 2005.

Affiliated with

Also associated with

Rating

3-cyano-quinoline derivatives with antiproliferative activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-cyano-quinoline derivatives with antiproliferative activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-cyano-quinoline derivatives with antiproliferative activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4177043